---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-036507"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:51:39.509770+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Omeros closes zaltenibart sale to Novo Nordisk for $240M upfront; repays debt, launches $100M buyback

## Summary
- Closed sale of zaltenibart to Novo Nordisk for $240M upfront; eligible for up to $2.1B in milestones plus tiered royalties on net sales.
- Used $72.6M of proceeds to repay $67.1M term loan, prepayment premium, interest; Credit Agreement terminated.
- Board authorized up to $100M share repurchase program for common stock with indefinite term.
- Remaining cash expected to fund >12 months of operations, including narsoplimab launch for TA-TMA.
- Pro forma financials show net income of $124.4M for FY2024 and net loss of $69.9M for 9M2025 after asset sale adjustments.

## SEC filing metadata
- accession: 0001437749-25-036507
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.02, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774925036507/0001437749-25-036507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774925036507/omer20251024_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-036507
- JSON: https://secwatch.observer/filing/0001437749-25-036507.json
- Plain text: https://secwatch.observer/filing/0001437749-25-036507.txt

## Source-grounded claims
- claim_id: aca73ca0a74476e092edf19bf152405c41eb3758
  claim: OMEROS CORP completed a disposition involving Novo Nordisk Health Care AG for upfront cash payment of $240.0 million at closing, plus potential milestone payments up to $1.81 billion (development and sales-based milestones) and tiered roy (closed 2025-11-25).
  evidence_excerpt: development and commercialization activities of both companies (the “Transaction”). At the closing of the Transaction (the “Closing”), Omeros received an upfront cash payment of $240.0 million, approximately $72.6 million of which was used to repay the Credit Agreement as described in Item 1.02 above. In addition, Omeros can receive (i) up to a total of $510 million in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285819/000143774925036507/0001437749-25-036507-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.